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Abstract
Background: Low dose statins are commonly used among Asians, because plasma low-density lipoprotein
cholesterol (LDL-C) reductions similar to those observed in Westerners are achieved at lower doses. We aimed to
assess the efficacy of low- and moderate-intensity statins for achieving plasma lipid targets in Thai type2 diabetes
(T2D) and to evaluate factors associated with greater LDL-C reduction by statins.
Methods: T2D patients who were treated with low- and moderate-intensity statins at the Siriraj Diabetes Clinic
during the January 2013 to December 2014 study period were eligible for inclusion(n = 978), 400 patients were
randomly recruited. Patients were classified into 1 of the following 2 groups according to their plasma LDL-C
reductions by statins (N = 393); very favorable response (LDL-C reduction ≥50%) or less favorable response (LDL-C
reduction <50%).
Results: Of the 400 patients, 41.3% were low-intensity statin users. Mean age was 64.4 ± 12.7 years, 64% were
female. Median duration of diabetes was 13.3 years and mean HbA1C was 8.1 ± 1.9%. Plasma LDL-C goal of
<100 mg/dl and <70 mg/dl was achieved in 84.3% and 38.0% respectively, with no significant difference between
the low- and moderate-intensity statin users. LDL-C reductions ≥50% can be achieved in 38.4%. Factors associated
with very favorable responses from statins were age, hypertension, patients with stable or reduced weight, and
better glycemic control.
Conclusion: Low- and moderate-intensity statins achieved plasma LDL-C goal of <100 mg/dl and <70 mg/dl in 84.
3%, and 38.4% of the patients respectively. Due to the improved response to lower doses observed in Asians, a
titration dosage strategy should be considered.
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Background
Type 2 diabetes (T2D) is an independent risk factor for
atherosclerotic cardiovascular disease (ASCVD) and has
been classified as coronary heart disease (CHD) risk
equivalent [1–3]. Statin treatment has been shown to be
effective in reducing ASCVD events both in primary and
secondary prevention [4, 5]. The American Diabetes As-
sociation 2016 guideline [6] and the American College
of Cardiology/American Heart Association 2013 guideline
[7] both recommended using moderate- and high-
intensity statins in all T2D patients, except those aged
<40 years without ASCVD risk factors. Low-, moderate-,
and high-intensity statins therapy are predicted to reduce
plasma low-density lipoprotein cholesterol (LDL-C) levels
from baseline by approximately <30%, 30% to <50%, and
≥50%, respectively [7]. Low-intensity statins are not
recommended in these guidelines for patients with T2D
[6, 7]. However, previous data suggested that Asians
achieved plasma LDL-C reductions that were similar to
those observed in Westerners, except at lower statin doses
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[8–11]. A proposed explanation for this dose-effect differ-
ence was genetic variability in drug metabolism [12].
Treatments with simvastatin 10 mg/day and atorvastatin
10 mg/day over 8 weeks at 6 Asian centers resulted in
average plasma LDL-C reductions of 35% and 43%, re-
spectively [10]. In addition, blood statin levels were re-
ported to be higher in Asians than in Westerners at the
same statin doses, which suggest an increased risk of sta-
tin toxicity in Asian population. Lee, et al. reported a dif-
ference in plasma LDL-C reduction response to
rosuvastatin between subjects of European and Asian an-
cestry living in Singapore [13]. Moreover, Asian subjects
had approximately twofold greater plasma exposure to
rosuvastatin than Caucasians, which was not the result of
body weight or environmental factors [13]. Although
high-intensity statin therapy has been used effectively and
safely in Asian patients especially ASCVD patients, most
statin side effects are dose-dependent [14–16]. Titration
of statin dosage is a common approach among Thai physi-
cians thus low- and moderate-intensity statins are com-
monly prescribed among Thai T2D patients without
ASCVD.
The aim of this study was to assess the efficacy of low-
and moderate-intensity statins for achieving plasma lipid
targets in Thai T2D patients, and to assess factors asso-
ciated with greater plasma LDL-C reductions during sta-
tin therapy.
Methods
This retrospective cohort study was conducted at Siriraj
hospital, Mahidol University– Thailand’s largest university-
based national tertiary referral center. All of the study
subjects are Asians. T2D patients who were treated with
low- and moderate-intensity statins at the Siriraj Diabetes
Clinic during the January 2013 to December 2014 study
period were eligible for inclusion. Patients were stratified
into 3 groups by statin intensity according to American
College of Cardiology/American Heart Association (ACC/
AHA) 2013 guideline; as low-, moderate-, or high-intensity
(Additional file 1). Patients were included if they met the
following criteria during the study period: (I) age ≥18 years;
(II) diagnosed with T2D; (III) received low- to moderate-
intensity stable statin doses for at least 2 months; and, (IV)
had baseline lipid profile laboratory investigation. The med-
ical records of all subjects were reviewed and demographic
and clinical data, including diabetic complications, medica-
tions used, and blood chemistry, were recorded. The pres-
ence of ASCVD was defined as the presence of CHD,
ischemic stroke, peripheral artery disease or aortic
aneurysm diagnosed during the data collection. The proto-
col for this study was approved by the Siriraj Institutional
Review Board (SIRB) ethical committee. This research was
done in accordance with the Ethical Principles of Medical
Research Involving Human Subjects outlined in the declar-
ation of Helsinki in 1975.
A total of 1,081 patients attended Siriraj Diabetes
Clinic during January 2013 to December 2014 and were
statin users. Low- and moderate-intensity statins were
prescribed in 978 (90.47%) of the patients while high-
intensity statins were prescribed in only 103 patents
(9.53%). Of the 978 low- to moderate-intensity statin
users and based on the results of the sample size for-
mula shown below, 400 patients were randomly selected
by using random sample numbers generating from an
Excel program (Fig. 1). Baseline plasma LDL-C level
before statin therapy was available in 393 patients.
Percentages of plasma LDL-C reduction by statin ther-
apy were calculated using the following formula:




Patients were classified into 1 of the following 2
groups according to their percentage plasma LDL-C re-
duction after statin treatments; very favorable (LDL-C
reduction ≥50%) or less favorable response (LDL-C re-
duction <50%). Factors associated with greater plasma
LDL-C reduction were analyzed (Fig. 1).
Sample size calculations
We estimated that low-and moderate-intensity statins
would achieve plasma LDL-C of <70 mg/dl in 35% of the
subjects based on our own previous study (unpublished). A
sample size of 350 subjects was required to obtain a 95%
confidence interval with a margin error of 5% according to
the formula: n = Zα
2 P(1 – P)/d2. A sample size was round
up to 400 subjects for approximately 14% sample loss.
Factors associated with greater plasma LDL-C reduc-
tions were calculated based on the formula using in the
case control study. If baseline LDL ≥160 mg/dl is preva-
lent 43% and 23%, respectively in the group with LDL-C
reduction ≥50% and <50%. A sample size of 124 per
Fig. 1 The Study Flow Chart
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group is required for a ratio of case to control of 1:1
with a 95% confidence and a power of 90%.
In order to achieve both objectives, the sample size of
400 is used in this study.
Statistical analysis
All statistical analyses were performed using SPSS
software version 20 (SPSS, Inc, Chicago, IL, USA). Cat-
egorical variables were compared using Fisher’s exact
test or chi-square analysis and continuous variables were
compared using Student’s t-test or Mann–Whitney U
test. Data are presented as numbers (%), percentages,
mean ± SD, or median. All statistical tests were 2-tailed.




Of 400 patients, 165 patients (41%) used low-intensity
statins and 235 patients (59%) used moderate-intensity
statins. Patient demographic and clinical data are sum-
marized in Table 1. Mean age of patients was 64.4 ±
12.7 years, and 64% were female. Study participants had
a long duration of diabetes, with a median duration of
13.3 years. Mean HbA1C was 8.1 ± 1.9%. In most pa-
tients, statin drugs had been prescribed for an extended
period of time. Median duration of statin use was
63 months. Patients who received moderate-intensity
statins had significantly (p < 0.05) higher prevalence of
ASCVD, CHD, chronic kidney disease (CKD), and
higher systolic blood pressure (SBP) than patients who
received low-intensity statins. Other clinical characteris-
tics were similar between the low and moderate groups.
Chronic diabetic complications were also not signifi-
cantly different between groups. Pre-statin plasma lipid
levels are showed in Table 1. Mean total cholesterol and
mean plasma LDL-C were 219.3 ± 45.6 mg/dl and 138.9
± 37.6 mg/dl, respectively. Patients who received
moderate-intensity statins had significantly higher base-
line (pre-statin treatment) plasma cholesterol, triglycer-
ide, and LDL-C levels than patients in the low-intensity
statin group. Pre-statin plasma HDL-C levels were also
significantly lower in moderate-intensity statin users
than in low-intensity statin users.
LDL-C goal achievement
We found that 337 patients (84.3%) who received low-
or moderate-intensity statins can achieve plasma LDL-C
goal of less than 100 mg/dl, and 152 patients (38%)
achieved LDL-C goal of less than 70 mg/dl (Fig. 2).
Interestingly, moderate-intensity statins did not result in
a significant greater LDL-C reduction goals achievement
rate than the low-intensity statins. In fact, low-intensity
statin users demonstrated a trend toward greater
achievement of LDL-C reduction <70 mg/dl than
moderate-intensity statin users. The percentages of
patients achieving plasma LDL-C goals in the low- and
moderate-intensity statin groups were 87.3% vs. 82.1%,
respectively for plasma LDL-C goal of <100 mg/dl, and
43.6% vs. 34.0%, respectively for LDL-C goal <70 mg/dl
(Fig. 2).
Percentages of plasma LDL-C reductions by statins
The median percentage of plasma LDL-C reduction by
statins of the overall participants (N = 393) were −34.6%,
while low- and moderate-intensity statin group had me-
dian percentages of plasma LDL-C reduction by −31.4%
and −36.1%, respectively. Moreover; we found that
75.9% of low-intensity statin users had plasma LDL-C
reduction greater than 30% from baseline, which is
higher than the LDL-C reduction expected in the West-
erners. Moreover 41.1% of moderate-intensity statin
users, and 34.5% of the low-intensity statin users had
plasma LDL-C reduction ≥50% from baseline which is
expected to achieved from high-intensity statins in the
Westerners (Fig. 3). As compared to low-intensity sta-
tins, moderate-intensity statins did not result in a greater
proportion of patients having percentage baseline LDL-
C reduction of ≥50% or 30% to <50% than low-intensity
statins (Fig. 3).
Factors predicting greater plasma LDL-C reduction with
statins
There were 38.4% (n = 151) of subjects who had plasma
LDL-C reduction ≥50% from baseline and this group
was defined as the very favorable response group. The
remaining participants who had plasma LDL-C reduc-
tion <50% were classified as the less favorable response
group (n = 242). Patients in the very favorable response
group were significantly older and had longer duration
of statin use than the lessfavorable response group.
Hypertension was more prevalent in the very favorable
response group. Moreover, the very favorable response
group had a significantly greater number of patients
who could maintain or reduce their body weight after
statin therapy was initiated, as compared to the lessfa-
vorable response group (Table 2). Blood chemistry re-
sults before statin treatment of both groups are shown
in Table 2. Subjects with better glycemic control had
greater LDL-C lowering response with low- and
moderate-intensity statins than subjects with poorer
glycemic controls. Mean baseline HbA1C were signifi-
cantly lower in the very favorable response group than
the less favorable response group (7.7% vs. 8.3%, p <
0.01). The very favorable response group had higher
mean plasma total cholesterol and LDL-C levels than
the less favorable response group (Table 2).
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Discussion
Low- and moderate-intensity statins were commonly
used in Thai T2D patients, and were prescribed in
34.04% and 56.43%, respectively among statin users
while high-intensity statins were prescribed in only
9.53%. We found that low- and moderate-intensity sta-
tins can achieve plasma LDL-C reduction goal of <100
and <70 mg/dl in 84.3% and 38% of the patients,
Table 1 Clinical Characteristics of the Study Participants
Characteristic Overall (n =400) Low-intensity statins (n = 165) Moderate-intensity statins (n = 235) p-value
Female 256(64.0%) 113(68.5%) 143(60.8%) 0.12
Age (mean ± SD, years) 64.4 ± 12.7 64.0 ± 13.5 64.7 ± 12.1 0.62
Duration of DM (median, years) 13 14 12 0.13
Duration of statins (median, months)a 63 63 61.5 0.46
Smoking 10/355(2.8%) 3/146 (2.1%) 7/209 (3.3%) 0.63
Drink alcohol 28/352 (8.0%) 7/146 (4.8%) 21/206 (10.2%) 0.06
Family history of CHD 5/186 (2.7%) 3/83 (3.6%) 2/103 (1.9%) 0.81
Weight before statin treatment (kg) 66.6 ± 13.1 66.8 + 13.4 66.4 + 12.9 0.74
Body weight at enrollment (kg) 67.9 ± 14.4 66.9 ± 12.5 68.5 ± 15.5 0.30
Body mass index (kg/m2) 26.4 ± 5.7 26.4 ± 4.8 26.4 ± 6.2 0.96
Waist circumference (cm) 93.5 ± 11.5 93.0 ± 11.7 93.9 ± 11.42 0.72
Systolic blood pressure (mmHg) 132.7 ± 14.8 130.7 ± 15.2 134.1 ± 14.4 0.02
Diastolic blood pressure (mmHg) 74.5 ± 11.0 73.47 ± 11.2 75.2 ± 10.9 0.13
Comorbidity
ASCVD 79/400 (19.8%) 24/165 (14.5%) 55/235 (23.4%) 0.03
CHD 57/400 (14.3%) 16/165 (9.7%) 41/235 (17.4%) 0.02
Stroke 27/400 (6.8%) 9/165 (5.5%) 18/235 (7.7%) 0.39
Peripheral artery disease 11/400 (2.8%) 3/165 (1.8%) 8/235 (3.4%) 0.52
Aortic aneurysm 2/400 (0.5%) 0/165 (0.0%) 2/235 (0.9%) 0.64
Hypertension 296/400 (74.0%) 124/165 (75.2%) 172/235 (73.2%) 0.66
Chronic kidney disease 106/400 (26.5%) 34/165 (20.6%) 72/235 (30.6%) 0.03
Diabetic retinopathy 0.88
No DR 232/347 (66.9%) 102/140 (72.9%) 130/207 (62.8%)
NPDR 83/347 (23.9%) 25/140 (17.9%) 58/207 (28.0%)
PDR 32/347 (9.2%) 13/140 (9.3%) 19/207 (9.2%)
Diabetic neuropathy 0.66
Normal 120/165 (72.7%) 45/65 (69.2%) 75/100 (75.0%)
Impaired monofilament test 30/165 (18.2%) 14/65 (21.5%) 16/100 (16.0%)
Foot ulcer 15/165 (9.1%) 6/65 (9.2%) 9/100 (9.0%)
Diabetic nephropathy 0.43
MAU < 30 mg/g creatinine 175/296 (59.1%) 73/118 (61.9%) 102/178 (57.3%)
MAU≥ 30 mg/g creatinine 121/296 (40.9%) 45/118 (38.1%) 76/178 (42.7%)
Pre-statin plasma lipid levels
Total cholesterol (mg/dl) 219.3 ± 45.6 211.9 ± 40.3 224.6 ± 48.4 0.01
Triglyceride (mg/dl) 157.3 ± 78.7 143.1 ± 67.8 167.2 ± 84.3 0.01
HDL (mg/dl) 51.0 ± 15.1 53.0 ± 15.5 49.5 ± 14.8 0.04
LDL-C (mg/dl) 138.9 ± 37.6 132 ± 33.6 143.7 ± 39.6 <0.01
Data presented as number (%), mean ± SD, or median; p-value < 0.05 indicates statistical significance. aDuration of statin was counted from the time of statin
initiation until the data collection date. Pre-statin plasma LDL-C levels were available in 393 patients
CHD, coronary heart disease; DM, diabetes mellitus; BMI, body mass index; ASCVD, atherosclerotic cardiovascular disease; DR, diabetic retinopathy; NPDR, non-
proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; MAU, microalbuminuria;. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol
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respectively. Moreover low- and moderate-intensity sta-
tins resulted in plasma LDL-C reduction ≥50% in 34.5%
and 41.1% of patients, respectively. In fact, plasma LDL
reductions greater than 50% from baseline are expected
to result from high-intensity statin therapy in the West-
erners [7, 15]. Overall our data demonstrated greater ef-
ficacy of plasma LDL-C reductions with low doses of
statins in Thai diabetic patients, which is consistent with
the results of other studies in Japanese [9], Korean [8],
and Chinese [10, 17] subjects. Matsuzawa Y, et al. found
that 5 mg of simvastatin in Asians obtained the same
LDL-C reduction effect as 20 mg of simvastatin use in
Westerners [9]. A possible explanation for the greater
effect of statin at lower doses may center on differences
in statin pharmacokinetics and pharmacogenetics be-
tween Asian and Western populations resulted in higher
blood statin levels in Asians than Westerners with the
same statin dosage [11–13, 17, 18].
Interestingly, moderate-intensity statins do not pro-
duce greater LDL-C goal achievement rate or greater
percentage of baseline LDL-C reduction, as compared
with low-intensity statins in Thai diabetic patients.
Doubling of statin dosage resulted in greater plasma
LDL-C reduction of approximately 6% [19, 20], thus
may explain the non-significant increase in LDL-C goal
achieving rate in our study. However, a meta-analysis of
statin trials reported greater CAD risk reduction with
high-intensity statins as compared to the lower intensity
statins [4]. It is still unclear whether this additional
benefit is due to the greater LDL-C reduction or from
other pleiotropic effects of statins. Moderate-potency
statins were more commonly used than low-potency sta-
tins in our clinic, thus moderate-potency statin users
were randomly recruited more into our study. The pres-
ence of ASCVD, the presence of cardiovascular risk fac-
tors such as hypertension, chronic kidney disease, and
higher pre-statin plasma lipid levels were associated with
physicians’ choice of using higher potency statins. These
are reasonable approach according to the recent guide-
lines [6, 7].
Our study found that factors associated with greater
plasma LDL-C reduction in response to low- and
moderate-intensity statins were older age, longer dur-
ation of statin usage, hypertension, weight maintenance
or weight loss during statin therapy, lower HbA1c, and
higher baseline plasma lipids. Some of these factors were
consistent with the previous studies. Con, et al. found
that the probability of attaining the LDL-C goal
increases with age [21]. Trompe, et al. studied character-
istics of non-responders and high responders of prava-
statin treatment among the elderly and found that
patients who did not respond well to pravastatin therapy
were, on average, 1 year younger [22]. Higher blood
statin level in the elderly might be another explanation
for the greater plasma LDL-C reduction response. The
finding of longer duration of statin usages in the very
favorable LDL-C reduction response group may also re-
flect the longer duration of hypercholesterolemia in the
older patients. In addition, the ability to maintain body
weight or lose weight predicts a better LDL-C lowering
response during statin treatment. We speculate that the
ability to maintain body weight or lose weight results
from an improved self-perception of one’s health status.
These patients may have healthier lifestyles and may en-
gage in regular exercise in addition to statin treatment,
so these patients may have better response to statin ther-
apy. Moreover, a better glycemic control was another
predictor of better LDL-C lowering response during sta-
tin therapy. This also supports the concept of better
self-care in this group.
Limitation
This study has some limitations. First, this was a retro-
spective study and plasma lipid levels were recorded
only at baseline before statins initiation and at the last
two visits. As such, biochemical changes between times
and between changes in medications were not investi-
gated. Second, we only evaluated low- and moderate-
intensity statins as they were most commonly prescribed
in Thailand for primary prevention of ASCVD;
Fig. 2 Plasma LDL-C Goal Achievement in Patients Treated with
Low- or Moderate-intensity Statins
Fig. 3 Percentage of Plasma LDL-C Reduction by Low- and Moderate-
intensity Statin Therapy
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Table 2 Demographic and Clinical Characteristics of Patients by LDL-C Reduction Group (<50% vs. ≥50%)
LDL-C reduction <50% (n = 242) LDL-C reduction ≥50% (n = 151) p-value
Female 152 (62.8%) 99 (65.6%) 0.58
Age (years) 63.2 ± 13 66.4 ± 12.1 0.02
Duration of DM (mo, median) 13 13 0.29
Duration of statin usage (mo, median) 56 88 <0.01
Smoking 7/215 (3.3%) 3/133 (2.3%) 0.86
Alcohol 17/213 (8.0%) 10/132 (7.6%) 0.89
Family history of CHD 1/112 (0.9%) 4/72 (5.6%) 0.08
Body mass index (kg/m2) 26.2 ± 4.9 26.6 ± 6.8 0.58
Weight before statin treatment (kg) 65.9 ± 12.6 67.4 ± 13.9 0.28
Waist circumference (cm) 94.6 ± 11.9 91.2 ± 10.4 0.19
Weight reduction 87/227 (38.3%) 68/138 (49.3%) 0.04
SBP (mmHg) 131.8 ± 14.3 74.9 ± 11.3 0.11
DBP (mmHg) 74.9 ± 11.3 73.8 ± 10.8 0.33
Comorbidities
CHD 35/242 (14.5%) 20/151 (13.2%) 0.74
Stroke 18/242 (7.4%) 9/151 (6.0%) 0.57
Peripheral artery disease 6/242 (2.5%) 5/151 (3.3%) 0.63
Aortic aneurysm 2/242 (0.8%) 0/151 (0.0%) 0.26
Hypertension 167/242 (69.0%) 124/151 (82.0%) <0.01
Chronic kidney disease 65/242 (26.9%) 40/151 (26.5%) 0.94
Diabetic retinopathy 0.79
Normal 135/206 (65.5%) 94/136 (69.1%)
NPDR 51/206 (24.8%) 30/136 (22.1%)
PDR 20/206 (9.7%) 12/136 (8.8%)
Diabetic neuropathy 0.75
Normal 75/105 (71.4%) 43/58 (74.1%)
Impaired Monofilament 21/105 (20.0%) 9/58 (15.5%)
Foot ulcer 9/105 (8.6%) 6/58 (10.4%)
Diabetic nephropathy 0.93
MAU≥ 30 mg/g creatinine 71/175 (40.6%) 48/117 (41.0%)
MAU < 30 mg/g creatinine 104/175 (59.4%) 69/117 (59.0%)
Statin potency 0.19
Low-intensity statin users 106/242 (43.8%) 56/151 (37.1%)
Moderate-intensity statin users 136/242 (56.2%) 95/151 (62.9%)
Pre-statin blood chemistry
Total cholesterol (mg/dl) 204.7 ± 43.8 242.4 ± 39.1 <0.01
Triglyceride (mg/dl) 153.5 ± 81.0 161.8 ± 74.6 0.35
HDL (mg/dl) 50.9 ± 16.3 51.1 ± 13.1 0.95
LDL-C (mg/dl) 125.7 ± 34.1 160.0 ± 33.2 <0.01
HbA1C (%) 8.3 ± 2.0 7.7 ± 1.6 <0.01
FBS (mg/dl, median) 158.9 169.4 0.32
Data presented as mean ± SD or median; p-value < 0.05 indicates statistical significance
CHD, coronary heart disease; DM, diabetes mellitus; BMI, body mass index; ASCVD, atherosclerotic cardiovascular disease; DR, diabetic retinopathy; NPDR, non-
proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; MAU, microalbuminuria; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation;
HDL-C, high-density lipoprotein cholesterol; FBS, fasting blood sugar
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therefore, our data cannot be applied to high-intensity
statins. Third, only 19.8% of our study population had
ASCVD. As such, our findings can be applied mainly to
T2D for primary prevention, but cannot be generalized
for use in secondary prevention. Moreover, in a real-
world setting, inter-individual variability in statin
responsiveness may be more evident [23, 24].
Conclusions
Thai diabetic patients primarily receive low- or
moderate-intensity statins. Low- and moderate-intensity
statins achieved the plasma LDL-C reduction goal of
<100 and <70 mg/dl in 84.3% and 38% of the patients,
respectively. Predictors of better response to statin ther-
apy were older age, stable or reduced weight, and better
glycemic control. Due to the improved response to lower
doses observed in Asians, a titration dosage strategy
should be considered.
Additional file
Additional file 1: Statin intensity classification according to American
College of Cardiology/American Heart Association (ACC/AHA) 2013
guideline. (PPTX 63 kb)
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